anti-HIgG(Fc)-C-DMDM ADC (CAT#: ADC-AA-006)

A: The anti-HIgG(Fc)-C-DMDM ADC consists of an anti-human IgG Fc specific polyclonal antibody linked through a cleavable linker to DMDM, a cytotoxic molecule that binds to DNA and causes DNA damage. This ADC targets cells expressing human IgG Fc, delivering the cytotoxic molecule directly to induce cell death.

A: The cleavable linker in this ADC is designed to release the cytotoxic drug DMDM upon entering targeted cells. This feature allows for the controlled release of the drug, enhancing the specificity of the ADC and reducing potential off-target effects.

A: This ADC specifically targets cells that have receptors for the Fc region of human IgG antibodies. These could include various immune cells involved in antibody-dependent cellular processes, making the ADC suitable for targeting certain immune-mediated conditions or cancers.

A: Using a secondary antibody that targets the Fc region allows for broader specificity and the potential to engage multiple primary antibodies. This can be particularly useful in complex therapeutic scenarios where multiple targets need to be engaged simultaneously.

A: The glycosylation of the Fc fragment is crucial for its interaction with Fc receptors on immune cells. This interaction enhances the ADC's ability to be internalized by target cells and activates downstream immune responses such as antibody-dependent cellular cytotoxicity (ADCC). These processes are integral to the therapeutic efficacy of the ADC, ensuring that the cytotoxic agent is delivered effectively to the target cells.